GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) » Definitions » Capex-to-Operating-Income

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Capex-to-Operating-Income : 2.32 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hainan Huluwa Pharmaceutical Group Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Hainan Huluwa Pharmaceutical Group Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-91.93 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥39.68 Mil.

Hence, Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 2.32.


Hainan Huluwa Pharmaceutical Group Co Capex-to-Operating-Income Historical Data

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Huluwa Pharmaceutical Group Co Capex-to-Operating-Income Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.37 0.39 1.61 3.18 2.57

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 5.63 3.83 1.44 2.32

Competitive Comparison of Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income falls into.



Hainan Huluwa Pharmaceutical Group Co Capex-to-Operating-Income Calculation

Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-489.2) / 190.414
=2.57

Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-91.934) / 39.678
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Huluwa Pharmaceutical Group Co  (SHSE:605199) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Hainan Huluwa Pharmaceutical Group Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Hainan Huluwa Pharmaceutical Group Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Headlines

No Headlines